MabCure Featured in GenomeWeb

MabCure, Inc. (OTCBB:MBCI) (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in a January 14, 2010 article published on GenomeWeb, the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics.

The cover story, written by Tony Fong and titled “MabCure Begins Clinical Trial for Antibody Technology for Use as Cancer Diagnostic,” describes the company’s “improvement over … strategies employed by most proteomics companies,” which rely on statistical differences in expression of normal proteins that may correlate with cancer. In contrast, MabCure is developing monoclonal antibodies against cancer-specific antigens (markers) which are unique to different types of cancers. In the case of ovarian cancer, MabCure’s approach “seeks to detect antigens specific to ovarian cancer in order to diagnose the disease with a high level of certainty.”

Highlighted in the piece is MabCure’s revamped hybridoma technology which is “…able to generate thousands of antibodies in about four to six weeks” versus classic hybridoma which is capable of generating only a few hundred in four to six months. The article quoted Dr. Amnon Gonenne, MabCure’s president, CEO, and co-founder, “…if you're looking to screen … a very large population, you need to be able to [make] very large libraries of antibodies.”

The article went on to discuss MabCure’s scientific strategy to create antibodies against new and unknown cancer markers. “Rather than develop antibodies against defined and well-known antigens, the company took the opposite approach: They generated and found antibodies against specific antigens without knowing a priori what they were.”

The article quoted Dr. Gonenne as saying, “…the company plans to extend the clinical trial to include centers in Europe for potential approval of a diagnostic in that market. Then, it would file with the FDA to market such a test in the US.”

Dr. Gonenne commented on the GenomeWeb coverage, “we are delighted to receive coverage of this caliber from a news organization as esteemed as GenomeWeb. Media coverage such as this affords us the opportunity to share our science with the rest of the scientific community and the public-at-large.”

About MabCure

MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs) which will be developed as diagnostic tools, imaging agents and drugs to treat lethal cancers. MabCure’s initial goal is to develop its novel MAbs as diagnostic tools for the detection of ovarian and prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit MabCure’s website at http://www.mabcure.com.

Forward-Looking Statement

Information provided in this press release may contain statements relating to current expectations, estimates, forecasts and projections about future events that are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally relate to Mabcure’s plans, objectives and expectations for future operations and are based upon its management's current estimates and projections of future results or trends. Actual future results may differ materially from those projected as a result of certain risks and uncertainties. For a discussion of such risks and uncertainties, see "Risk Factors" as described in Mabcure’s filings with the Securities and Exchange Commission.

MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024